دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
In the Literature
doi : 10.1093/cid/ciac093
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages i–ii
Congenital Human Cytomegalovirus Infection Is Associated With Decreased Transplacental IgG Transfer Efficiency Due to Maternal Hypergammaglobulinemia
Eleanor C Semmes, Shuk Hang Li, Jillian H Hurst, Zidanyue Yang, Donna Niedzwiecki, Genevieve G Fouda, Joanne Kurtzberg, Kyle M Walsh, Sallie R Permar
doi : 10.1093/cid/ciab627
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1131–1140
Placentally transferred maternal immunoglobulin G (IgG) protects against pathogens in early life, yet vertically transmitted infections can interfere with transplacental IgG transfer. Although human cytomegalovirus (HCMV) is the most common placentally-transmitted viral infection worldwide, the impact of congenital HCMV (cCMV) infection on transplacental IgG transfer has been underexplored.
Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020
Patrick Sean Sullivan, Aaron J Siegler, Kayoko Shioda, Eric W Hall, Heather Bradley, Travis Sanchez, Nicole Luisi, Mariah Valentine-Graves, Kristin N Nelson, Mansour Fahimi, Amanda Kamali, Charles Sailey, Benjamin A Lopman
doi : 10.1093/cid/ciab626
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1141–1150
Reported coronavirus disease 2019 (COVID-19) cases underestimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. We conducted a national probability survey of US households to estimate cumulative incidence adjusted for antibody waning.
Mother to Infant Transmission of Hepatitis B Virus in the Face of Neonatal Immunization Is Not Necessarily Primary Vaccine Failure
Samreen Ijaz, Jade Derrick, Justin Shute, Georgina Ireland, Iain Hayden, Siew Lin Ngui, Sema Mandal, Richard S Tedder
doi : 10.1093/cid/ciab622
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1151–1157
Surveillance programs undertaken in infants born to mothers with hepatitis B virus (HBV) provide an opportunity to analyze virological markers from the neonate and early infancy. These data inform on mechanisms of HBV transmission and how available interventions can be better used for control of HBV infections arising at the mother/child interface.
Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada
Danuta M Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R Tyson, Eleni Galanis, Monika Naus, David M Patrick, Hind Sbihi, Shiraz El Adam, Bonnie Henry, Linda M N Hoang, Manish Sadarangani, Agatha N Jassem, Mel Krajden
doi : 10.1093/cid/ciab616
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1158–1165
Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included relatively few elderly participants.
Longitudinal Assessment of Coronavirus Disease 2019 Vaccine Acceptance and Uptake Among Frontline Medical Workers in Los Angeles, California
Megan Halbrook, Adva Gadoth, Rachel Martin-Blais, Ashley N Gray, Saman Kashani, Clayton Kazan, Brian Kane, Nicole H Tobin, Kathie G Ferbas, Grace M Aldrovandi, Anne W Rimoin
doi : 10.1093/cid/ciab614
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1166–1173
Sentiments of vaccine hesitancy and distrust in public health institutions have complicated the government-led coronavirus disease 2019 (COVID-19) vaccine control strategy in the United States. As the first to receive the vaccine, COVID-19 vaccine attitudes among frontline workers are consequential for COVID-19 control and public opinion of the vaccine.
US Hospitalizations and 60-Day Readmission Rates Associated With Herpes Simplex Virus Encephalitis: Analysis of All Cause Readmissions and Encephalopathy Associated Readmissions
Michael A Hansen, Rodrigo Hasbun
doi : 10.1093/cid/ciab613
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1174–1182
Herpes simplex encephalitis (HSE) is the most common cause of encephalitis hospitalizations. We sought to describe and analyze features associated with all cause readmissions and encephalopathy associated readmissions amongst HSE cases.
Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020
Kevin Outterson, Ebiowei S F Orubu, John Rex, Christine Ã…rdal, Muhammad H Zaman
doi : 10.1093/cid/ciab612
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1183–1190
Inaccessibility of medicines in low- and middle-income countries is a frequent challenge. Yet it is typically assumed that high-income countries have complete access to the full arsenal of medicines. This study tests this assumption for new antibacterials, which are saved as a last resort in order to prevent the development of resistance, resulting in insufficient revenues to offset costs. Prior studies report only regulatory approval, missing the important lag that occurs between approval and commercial launch, although some antibiotics never launch in some countries.
Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study
Jessica Seeßle, Tim Waterboer, Theresa Hippchen, Julia Simon, Marietta Kirchner, Adeline Lim, Barbara Müller, Uta Merle
doi : 10.1093/cid/ciab611
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1191–1198
Long COVID is defined as the persistence of symptoms beyond 3 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To better understand the long-term course and etiology of symptoms we analyzed a cohort of patients with COVID-19 prospectively.
Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area
Andreas Wångdahl, Klara Sondén, Katja Wyss, Christine Stenström, David Björklund, Jessica Zhang, Helena Hervius Askling, Christina Carlander, Urban Hellgren, Anna Färnert
doi : 10.1093/cid/ciab610
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1199–1207
The effect of primaquine in preventing Plasmodium vivax relapses from dormant stages is well established. For Plasmodium ovale, the relapse characteristics and the use of primaquine is not as well studied. We set to evaluate the relapsing properties of these 2 species, in relation to primaquine use among imported malaria cases in a nonendemic setting.
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status
Sheila F Lumley, Gillian Rodger, Bede Constantinides, Nicholas Sanderson, Kevin K Chau, Teresa L Street, Denise O’Donnell, Alison Howarth, Stephanie B Hatch, Brian D Marsden, Stuart Cox, Tim James, Fiona Warren, Liam J Peck, Thomas G Ritter, Zoe de Toledo, Laura Warren, David Axten, Richard J Cornall, E Yvonne Jones, David I Stuart, Gavin Screaton, Daniel Ebner, Sarah Hoosdally, Meera Chand, Derrick W Crook, Anne-Marie O’Donnell, Christopher P Conlon, Koen B Pouwels, A Sarah Walker, Tim E A Peto, Susan Hopkins, Timothy M Walker, Nicole E Stoesser, Philippa C Matthews, Katie Jeffery, David W Eyre, Oxford University Hospitals Staff Testing Group
doi : 10.1093/cid/ciab608
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1208–1219
Natural and vaccine-induced immunity will play a key role in controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. SARS-CoV-2 variants have the potential to evade natural and vaccine-induced immunity.
Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2
Louis Grandjean, Anja Saso, Arturo Torres Ortiz, Tanya Lam, James Hatcher, Rosie Thistlethwayte, Mark Harris, Timothy Best, Marina Johnson, Helen Wagstaffe, Elizabeth Ralph, Annabelle Mai, Caroline Colijn, Judith Breuer, Matthew Buckland, Kimberly Gilmour, David Goldblatt,
doi : 10.1093/cid/ciab607
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1220–1229
Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been shown to neutralize the virus in vitro and prevent disease in animal challenge models on reexposure. However, the current understanding of SARS-CoV-2 humoral dynamics and longevity is conflicting.
Prevalence of Oral Human Papillomavirus Infection: Impact of Sex, Race/Ethnicity, and Vaccination Status
Abbey B Berenson, Jacqueline M Hirth, Mihyun Chang
doi : 10.1093/cid/ciab605
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1230–1236
Prior studies have demonstrated differences in oral human papillomavirus (HPV) prevalence by sex and race/ethnicity. In this study, we examined the impact of vaccination on these disparities.
Cytomegalovirus Viremia and Clinical Outcomes in Kenyan Children Diagnosed With Human Immunodeficiency Virus (HIV) in Hospital
Dalton Wamalwa, Irene Njuguna, Elizabeth Maleche-Obimbo, Emily Begnel, Daisy J Chebet, Judith A Onyango, Lisa Marie Cranmer, Meei-Li Huang, Barbra A Richardson, Michael Boeckh, Grace John-Stewart, Jennifer Slyker
doi : 10.1093/cid/ciab604
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1237–1246
Cytomegalovirus (CMV) viremia is common in human immunodeficiency virus (HIV) infection and is associated with worse long-term outcomes. To date, no studies have assessed CMV viremia in children diagnosed with HIV in hospital.
Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial
Joseph E Tota, Anna R Giuliano, Stephen E Goldstone, Brady Dubin, Alfred Saah, Alain Luxembourg, Christine Velicer, Joel M Palefsky
doi : 10.1093/cid/ciab603
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1247–1256
In men, the incidence of human papillomavirus (HPV)–related cancer is rising, but data regarding male HPV infection and seroprevalence are available from only a few countries.
Midline Destructive Lesions in Previously Healthy Adult
Elisabeth Gómez-Moyano, Silvestre MartÃnez GarcÃa, Maria Ayala-Blanca, Francisco Jimenez Oñate, Leandro MartÃnez Pilar
doi : 10.1093/cid/ciz559
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1257–1259
Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data
Catharine I Paules, Shannon K Gallagher, Rekha R Rapaka, Richard T Davey, Sarah B Doernberg, Robert Grossberg, Noreen A Hynes, Philip O Ponce, William R Short, Jocelyn Voell, Jing Wang, Otto O Yang, Cameron R Wolfe, David C Lye, Lori E Dodd, Constance A Benson
doi : 10.1093/cid/ciab695
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1260–1264
This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.
COVID-19 Outbreak Associated With a Fitness Center—Minnesota, September–November 2020
Tara Suhs, Daniel Gerlach, Jacob Garfin, Alexandra Lorentz, Melanie Firestone, Meaghan Sherden, Katie Hackman, Talor Gray, Samantha Siebman, Haley Wienkes, Kelley Vilen, Xiong Wang, Kathy Como-Sabetti, Richard Danila, Kirk Smith, Carlota Medus
doi : 10.1093/cid/ciab653
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1265–1267
The Minnesota Department of Health investigated a coronavirus disease 2019 (COVID-19) outbreak at a fitness center in Olmsted County, Minnesota. Twenty-three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (5 employees and 18 members) were identified. An epidemiological investigation supported by whole genome sequencing demonstrated that transmission of SARS-CoV-2 occurred at the fitness center despite following recommended prevention strategies.
The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
Bezawit A Woldemeskel, Andrew H Karaba, Caroline C Garliss, Evan J Beck, Kristy H Wang, Oliver Laeyendecker, Andrea L Cox, Joel N Blankson
doi : 10.1093/cid/ciab648
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1268–1270
Previous studies have shown that certain vaccines induce suboptimal responses in people living with human immunodeficiency virus (HIV, PLWH). However, responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors.
Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients
Arvind Gharbharan, Corine H GeurtsvanKessel, Carlijn C E Jordans, Marc Blaauw, Marjolein van der Klift, Robert-Jan Hassing, Marijn Smits-Zwinkels, Maaike Meertens, Ella C van den Hout, Anne Marie de Man, Ilse Hageman, Susanne Bogers, C Ellen van der Schoot, Francis Swaneveld, Adam A Anas, Casper Rokx, Bart J A Rijnders
doi : 10.1093/cid/ciab647
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1271–1274
Twenty-five B-cell–depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.
Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination
Crystal M North, Amy Barczak, Robert H Goldstein, Brian C Healy, Dianne M Finkelstein, Delaney D Ding, Andy Kim, Julie Boucau, Bennett Shaw, Rebecca F Gilbert, Tammy Vyas, Zahra Reynolds, Katherine J Siddle, Bronwyn L MacInnis, James Regan, James P Flynn, Manish C Choudhary, Jatin M Vyas, Karl Laskowski, Anand S Dighe, Jacob E Lemieux, Jonathan Z Li, Lindsey R Baden, Mark J Siedner, Ann E Woolley, Chana A Sacks
doi : 10.1093/cid/ciab643
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1275–1278
The impact of coronavirus disease 2019 vaccination on viral characteristics of breakthrough infections is unknown. In this prospective cohort study, incidence of severe acute respiratory syndrome coronavirus 2 infection decreased following vaccination. Although asymptomatic positive tests were observed following vaccination, the higher cycle thresholds, repeat negative tests, and inability to culture virus raise questions about their clinical significance.
Coronavirus Disease 2019–Associated Mucormycosis: Risk Factors and Mechanisms of Disease
Shivakumar Narayanan, Joel V Chua, John W Baddley
doi : 10.1093/cid/ciab726
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1279–1283
The severe surge of coronavirus disease 2019 (COVID-19) cases on the Indian subcontinent in early 2021 was marked by an unusually high number of COVID-19–associated mucormycosis (CAM) cases reported during this same period. This is significantly higher than predicted based on available data about prevalence and risk factors for this condition. This may be due to an unusual alignment of multiple risk factors for this condition.
Envisioning Future Urinary Tract Infection Diagnostics
Robin Patel, Christopher R Polage, Jennifer Dien Bard, Larissa May, Francesca M Lee, Valeria Fabre, Mary K Hayden, Sarah D B Doernberg, David A Haake, Barbara W Trautner, Larissa Grigoryan, Ephraim L Tsalik, Kimberly E Hanson
doi : 10.1093/cid/ciab749
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1284–1292
Urinary tract infections (UTIs) are among the most common bacterial infections in the United States and are a major driver of antibiotic use, both appropriate and inappropriate, across healthcare settings. Novel UTI diagnostics are a strategy that might enable better UTI treatment.
Clinical Efficacy and Safety of Albendazole and Other Benzimidazole Anthelmintics for Rat Lungworm Disease (Neuroangiostrongyliasis): A Systematic Analysis of Clinical Reports and Animal Studies
John Jacob, Argon Steel, Zhain Lin, Fiona Berger, Katrin Zöeller, Susan Jarvi
doi : 10.1093/cid/ciab730
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1293–1302
The safety and efficacy of benzimidazole anthelmintics for the treatment of rat lungworm disease (neuroangiostrongyliasis) have been questioned regardless of numerous experimental animal studies and clinical reports. In this review, 40 of these experimental animal studies and 104 clinical reports are compiled with a focus on albendazole.
Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria
Sharon Ong’uti, Mary Czech, Elizabeth Robilotti, Marisa Holubar
doi : 10.1093/cid/ciab757
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1303–1312
Cefiderocol is a novel injectable siderophore cephalosporin that hijacks the bacterial iron transport machinery to facilitate cell entry and achieve high periplasmic concentrations. It has broad in vitro activity against gram-negative bacteria, including multidrug-resistant (MDR) organisms such as carbapenem-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii.
Undetected and Relatively Sustained Severe Acute Respiratory Syndrome Coronavirus 2 Circulation Worldwide During 2019
Stefano Petti
doi : 10.1093/cid/ciab727
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1313–1314
Working HAND in HAND: Central Nervous System Complications in People with Human Immunodeficiency Virus
Leah H Rubin, Beau M Ances
doi : 10.1093/cid/ciab723
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Page 1314
Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Chloé Dimeglio, Fabrice Herin, Isabelle Da-Silva, Isabelle Jougla, Claire Pradere, Marion Porcheron, Guillaume Martin-Blondel, Sabine Chapuy-Regaud, Jacques Izopet
doi : 10.1093/cid/ciab705
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1315–1316
Rifampin for Staphylococcal Prosthetic Joint Infection: Do We Still Need a Randomized Controlled Trial?
Henk Scheper, Mark G J De Boer
doi : 10.1093/cid/ciab704
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1316–1318
Reply to Scheper and De Boer
Marjan Wouthuyzen-Bakker, Alex Soriano
doi : 10.1093/cid/ciab706
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Page 1318
Letter to editor regarding “Clinical Presentation and Outcomes of Pregnant Women With Coronavirus Disease 2019: A Systematic Review and Meta-analysis�
Jianghui Cai, Yonghong Lin, Meng-Jun Wu
doi : 10.1093/cid/ciab690
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Page 1319
Reply to Wu, et al
Reem Matar, M Hassan Murad, Layan Alrahmani
doi : 10.1093/cid/ciab694
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Pages 1319–1320
Correction to: Dose, Timing, and Spectrum of Prenatal Antibiotic Exposure and Risk of Childhood Asthma
Kedir N Turi, Tebeb Gebretsadik, Tan Ding, Andrew Abreo, Cosby Stone, Tina V Hartert, Pingsheng Wu
doi : 10.1093/cid/ciac148
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Page 1321
Erratum to: Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa
doi : 10.1093/cid/ciab803
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Page 1321
Erratum to: Characterization of an Asymptomatic Cohort of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Individuals Outside of Wuhan, China
Yubo Wang, Yong He, Jin Tong, Yalan Qin, Ting Xie, Jianghua Li, Jianrong Li, Jianhua Xiang, Yong Cui, Elizabeth S Higgs, Jianglin Xiang
doi : 10.1093/cid/ciab530
Clinical Infectious Diseases, Volume 74, Issue 7, 1 April 2022, Page 1322
